Endpoints News Apr 9, 2026 Roche dips into DACs with existing partner C4 Therapeutics for $20M upfront
Endpoints News Mar 20, 2026 Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial
Endpoints News Feb 9, 2026 #ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
Endpoints News Jan 8, 2026 Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial
Endpoints News Jan 8, 2026 Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C
Endpoints News Jan 8, 2026 Former Genentech leaders’ protein degrader startup EpiBiologics nets $107M
Endpoints News Dec 10, 2025 #SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%
Endpoints News Dec 4, 2025 Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatiron